| 1. |
- Johansson, Torsten, et al.
(författare)
-
Intra- and Postoperative Cerebral Complications of Open-Heart Surgery
- 1995
-
Ingår i: Scandinavian Cardiovascular Journal. - : Informa Healthcare. - 1401-7431 .- 1651-2006. ; 29:1, s. 17-22
-
Tidskriftsartikel (refereegranskat)abstract
- A consecutive series of 1400 patients who had undergone open-heart surgery was retrospectively reviewed concerning postoperative cerebral dysfunction. The 30-day mortality was 1.6%. Forty-one patients (2.9%) showed signs of cerebral dysfunction, which proved fatal in seven cases. Neurologic symptoms were observed immediately after surgery in 14 patients, suggesting intraoperative damage. In 20 others there was an interval between surgery and the onset of cerebral symptoms, which in 12 cases were preceded by supraventricular tachycardia. Computed tomographic scans were performed on 27 patients and showed recent brain infarction in 22. No bleeding was found. At followup 34 of the 41 patients were alive, 21 of them with neurologic sequelae and 13 reporting complete recovery. Nineteen of the 34 survivors experienced no diminution of quality of life. Since half of the cerebral complications occurred postoperatively, more aggressive prevention and management of supraventricular tachyarrhythmia and anticoagulation therapy should be considered.
|
|
| 2. |
- Fransson, Christer, 1956, et al.
(författare)
-
Prevalence of subjects with progressive bone loss at implants.
- 2005
-
Ingår i: Clinical oral implants research. - : Wiley. - 0905-7161. ; 16:4, s. 440-6
-
Tidskriftsartikel (refereegranskat)abstract
- AIM: The aim of the present study was to assess the prevalence of subjects with progressive bone loss at implants with a function time of at least 5 years. MATERIAL AND METHODS: Radiographs of 1346 patients who had attended annual follow-up visits at the Brånemark Clinic, Public Dental Services, Gothenburg, Sweden were retrieved. Six hundred and sixty-two subjects fulfilled the inclusion criteria. Thus, they all had been provided with implant-supported (Brånemark System) Nobel BioCare, Gothenburg, Sweden) fixed partial or complete dentures or single-tooth replacements with a documented function time in radiographs of at least 5 years. Implants that demonstrated progressive bone loss to a level of > or =3 threads of an implant were detected. The number of subjects who exhibited one or more implants with progressive bone loss to the threshold level was recorded. RESULTS: Twenty-eight percent of 662 included subjects had one or more implants with progressive bone loss. A logistic regression analysis revealed that the individuals in this group carried a significantly larger number of implants than the subjects in whom no implants with progressive loss were detected (6 vs. 4.8). Furthermore, >30% of the subjects in the group with progressive bone loss had > or =3 identified implants and that about 33% of all such implants in this group exhibited extensive bone loss. Out of the total 3413 implants included in the study, 423 implants (12.4%) demonstrated progressive bone loss. CONCLUSION: It is suggested that the prevalence of progressive bone loss at implants assessed from subject-based data is higher than that evaluated from implant-based data.
|
|
| 3. |
- Zhou, Qin, et al.
(författare)
-
The C-terminal amidated analogue of the Substance P (SP) fragment SP (1-7) attenuates the expression of naloxone- precipitated withdrawal in morphine dependent rats
- 2009
-
Ingår i: Peptides. - : Elsevier BV. - 0196-9781 .- 1873-5169. ; 30:12, s. 2418-2422
-
Tidskriftsartikel (refereegranskat)abstract
- We previously demonstrated that intracerebroventricular (i.c.v.) administration of the substance P (SP) aminoterminal fragment SP(1-7) attenuates the expression of morphine withdrawal in the male rat. In this study we have used a synthetic analogue of this peptide, i.e. the SP(1-7) amide showing higher binding potency than the native heptapeptide, in a similar experimental set-up. Thus, Wistar male rats were made tolerant to morphine by daily injections of the opiate during 8 days. Following peptide administration (i.c.v.) and a subsequent naloxone challenge a variety of physical syndromes of withdrawal were recorded. We observed that the SP(1-7) amide potently and dose-dependently reduced several signs of reaction to morphine withdrawal. Interestingly, the effect of the peptide amide was significantly attenuated by the addition of the sigma agonist (+)-SKF-10047. We conclude that the SP(1-7) amide mimics the effect of the native SP fragment and that the mechanisms for its action involve a sigma receptor site.
|
|
